Tom Wilemon

July 19, 2023

Holowatyj receives National Cancer Institute MERIT Award

Vanderbilt’s Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

By Tom Wilemon
Research by Ann Richmond, PhD, second from left, Chi Yan, PhD, left, Kensey Bergdorf, PhD, JinMing Yang, PhD, and colleagues is leading to new insights on melanoma tumor formation and growth.
June 29, 2023

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

By Tom Wilemon
June 21, 2023

Three Vanderbilt physicians named ASCO fellows

Three Vanderbilt-Ingram Cancer Center physicians were recently named fellows of the American Society of Clinical Oncology.

By Tom Wilemon
June 15, 2023

New treatment option for metastatic colorectal cancer prolongs survival

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

By Tom Wilemon
June 15, 2023

Early-onset CRC germline genetic differences identified by race, ethnicity

A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.

By Tom Wilemon
June 8, 2023

Enhanced treatment helps fast nicotine metabolizers quit smoking

A study from Vanderbilt researchers has found that enhanced treatment support can help smokers who have more difficulty quitting because they are fast metabolizers of nicotine.

By Tom Wilemon
June 5, 2023

Study discovers that tumor mutation burden predicts survival outcome

The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.
By Tom Wilemon
May 31, 2023

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
By Tom Wilemon
May 11, 2023

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.
By Tom Wilemon
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.
By Tom Wilemon
April 27, 2023

Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
By Tom Wilemon
April 26, 2023

VICC Scientific Retreat focuses on emerging technologies

The Vanderbilt-Ingram Cancer Center 24th Annual Scientific Retreat will be held from 8:30 am to 3 pm, May 23, in the Vanderbilt Student Life Center.
By Tom Wilemon
1 2 3 4 5 6 … 35